Genmab
1,447.5
DKK
+0.17 %
GMAB
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
24 following
+0.17%
-6.58%
-21.5%
-27.7%
-32.83%
-34.8%
-47.06%
-4.3%
+4,144.87%
www.genmab.com/investors
Genmab is a pharmaceutical company. The company specializes in the research and development of antibodies, which are mainly used in the treatment of cancer patients with lymphatic leukemia and solid tumors. Research and development are based on the company's own developed technology platform and operations are held on a global level. Genmab was founded in 1999 and is headquartered in Copenhagen, Denmark.
Revenue
16.47B
EBIT %
32.3 %
P/E
21.72
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Copenhagen
GMAB
Daily low / high price
1,436 / 1,458
DKK
Market cap
95.79B DKK
Turnover
128.38M DKK
Volume
89K
ShowingAll content types
Genmab to Present at Jefferies London Healthcare Conference
Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools